Palisade Bio Inc. (PALI) Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035

Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the company will be granted a patent from the European Patent Office (EPO) covering its lead investigational drug product, LB1148. The patent will publish on December 22, 2021, and provide protection until 2035.

“With the European patent grant, this greatly strengthens the IP protection of our lead drug candidate LB1148 for the global pharmaceutical market. This grant builds upon the corresponding patents in the United States, China, Australia, Japan, India, Mexico, and Taiwan,” said Thomas Hallam, Ph.D., CEO of Palisade Bio. “We are continuing to strengthen patent protections for LB1148 and its uses across the globe as we advance our clinical studies with LB1148.”

You May Also Be Interested In

• Palisade Bio Inc. (PALI) Enters Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
• Mr. Cooper Group (COOP) Appoints Ranjit Bhattacharjee as CIO and President, Kevin Barker as SVP of Corporate Finance
• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts